One-Shot cell therapy tested for stubborn autoimmune blood disorders
NCT ID NCT07441525
Summary
This early-phase study is testing a new 'universal' CAR-T cell therapy called RD06-05 in adults with severe autoimmune blood diseases that haven't responded well to standard treatments. The main goal is to check the safety of two different doses and see how well the therapy works to control the diseases. Researchers will monitor patients closely for side effects and signs of improvement in their blood counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.